Methylation of the SMAD3 promoter, not only in Infant Immune Study neonates but also in two replication cohorts (the Manchester Asthma and Allergy Study and the Childhood Origins of ASThma study), was selectively and significantly increased in neonates born to asthmatic mothers and was associated with childhood asthma risk. Here, SMAD3 is linked to asthma.